2019•Journal of Clinical Pharmacy and TherapeuticsOpen access

Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumab：A case report

Hui Gan, Ling Wang, Wei Fu, Jinjin Zhang, Mingxia Yu, Guanghui Liu

Abstract

WHAT IS KNOWN AND OBJECTIVE: Omalizumab is effective as an add-on drug to treat severe persistent allergic asthma. However, delayed hypersensitivity reactions to omalizumab may deprive patients of its use. Rapid subcutaneous desensitization could be a solution. CASE DESCRIPTION: A 61-year-old man developed a delayed allergy to omalizumab after the first injection. A 14-step desensitization procedure was applied to the patient and was successful. WHAT IS NEW AND CONCLUSION: Delayed hypersensitivity reactions to omalizumab are rare, but they may cause the interruption of drug usage. Desensitization to omalizumab could be a possible solution.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Omalizumab, Desensitization (medicine), Medicine, Drug allergy, Allergy, Allergic reaction, Drug, Anesthesia